Physician profile
James Lumeng
NPI 1346387966
$44,530.46
in general payments reported to CMS, 2019-2025
48 companies · $4,329 in 2025
The $4,329 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,864 · 2020: $3,837 · 2021: $7,041 · 2022: $6,539 · 2023: $5,820 · 2024: $7,101 · 2025: $4,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $93.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,156.72 |
| Education | $93.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,056.65 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,630.50 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $2,565.41 | 2021-2025 | |
| Lilly USA, LLC | $2,462.68 | 2019-2025 | Mounjaro, Ebglyss, Jardiance |
| Janssen Pharmaceuticals, INC | $2,378.76 | 2019-2024 | Xarelto |
| Abbvie INC. | $2,322.63 | 2019-2024 | |
| Novo Nordisk INC | $2,301.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $2,097.70 | 2019-2025 | Opdivo, Sotyktu, Cobenfy |
| Amarin Pharma, INC. | $1,665.58 | 2019-2022 | |
| Amgen INC. | $1,490.04 | 2019-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,463.04 | 2019-2024 | |
| Johnson & Johnson Health Care Systems INC. | $1,397.93 | 2019-2025 | Rybrevant, Carvykti, Tremfya |
| Esperion Therapeutics, INC. | $1,394.73 | 2020-2025 | Nexletol, Nexlizet |
| Janssen Scientific Affairs, LLC | $917.73 | 2019-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $840.87 | 2022-2025 | Rexulti |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lumeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.